A Study of GENEVAX-HIV, a Possible Vaccine

NCT00002232 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2005-06-24

No results posted yet for this study

Summary

The purpose of this study is to see if it is safe to give GENEVAX-HIV, a potential HIV vaccine, to HIV-negative volunteers. The study also compares the effects of GENEVAX-HIV injected into the muscle to the effects of the drug when injected into the skin.

Conditions

  • HIV Infections
  • HIV Seronegativity

Interventions

BIOLOGICAL

APL 400-003

Sponsors & Collaborators

  • Wyeth-Lederle Vaccines

    lead INDUSTRY

Principal Investigators

  • Merlin Robb

Study Design

Purpose
PREVENTION
Masking
DOUBLE

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002232 on ClinicalTrials.gov